Procter & Gamble Health Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹382 Cr +17.5% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
P&

Procter & Gamble Health Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Procter & Gamble Health Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹364Cr
+7.4% YoY
−1.6% QoQ
Net profit
₹96Cr
+45.5% YoY
+1.1% QoQ
Margin
27%
0 pp YoY
−10 pp QoQ

Based on Procter & Gamble Health Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹5,416
Market cap₹9.1K Cr
P/E27.4

The short version

FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).

From Procter & Gamble Health Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).
  • Profit after tax (PAT) increased by +30% in the same period (Page 8).
  • Net Sales showed a +7% CAGR over the past 5 years (Page 27).
  • PAT grew at a +13% CAGR over 5 years (Page 27).

2 more points from Procter & Gamble Health Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Procter & Gamble Health Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Procter & Gamble Health Ltd said on order book & pipeline — free account, 30 seconds.

Procter & Gamble Health Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Procter & Gamble Health Ltd Q1 FY27 results — key figures

Procter & Gamble Health Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue364339+7.4%370-1.6%
Operating profit (EBITDA)10090+11.1%136-26.5%
Operating margin27%27%0 pp37%-10 pp
Profit before tax12989+44.9%133-3%
Net profit (PAT)9666+45.5%95+1.1%
EPS (₹)57.9239.87+45.3%56.99+1.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Procter & Gamble Health Ltd Q1 FY27 results?

FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).

What is Procter & Gamble Health Ltd share price analysis?

Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.